Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Terhi Tapiainen, University of Oulu
ClinicalTrials.gov Identifier:
NCT01244581
First received: November 18, 2010
Last updated: June 19, 2012
Last verified: June 2012

November 18, 2010
June 19, 2012
September 1999
June 2012   (final data collection date for primary outcome measure)
Time (days) to disappearance of middle ear effusion [ Time Frame: Within 60 days ] [ Designated as safety issue: No ]
Disappearance of middle ear effusion is defined as the first day of receiving a normal tympanogram (A-curve) in tympanometry.
Time (days) to disappearance of middle ear effusion [ Designated as safety issue: No ]
Disappearance of middle ear effusion is defined as the first day of receiving a normal tympanogram (A-curve) in tympanometry.
Complete list of historical versions of study NCT01244581 on ClinicalTrials.gov Archive Site
Time (days) to disappearance of pain [ Time Frame: Within 60 days ] [ Designated as safety issue: No ]
Time (days) to disappearance of pain [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry
Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry

The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry performed by families and study physicians.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Otitis Media, Suppurative
  • Drug: Amoxicillin-clavulanate
    Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
    Other Name: Clavurion
  • Drug: Placebo
    Placebo mixture in two daily doses for 7 days
  • Experimental: Amoxicillin-clavulanate
    Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
    Intervention: Drug: Amoxicillin-clavulanate
  • Placebo Comparator: Placebo
    Interventions:
    • Drug: Amoxicillin-clavulanate
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children with acute otitis media

Exclusion Criteria:

  • Amoxicillin allergy
  • Tympanic membrane perforation
  • Tympanostomy tubes (current)
  • Complication of acute otitis media such as mastoiditis
Both
up to 16 Years
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT01244581
OYS_Tapiainen_001
No
Terhi Tapiainen, University of Oulu
University of Oulu
Not Provided
Study Director: Matti Uhari, Professor University of Oulu
Principal Investigator: Terhi Tapiainen, MD, PhD University of Oulu
University of Oulu
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP